预约演示
更新于：2026-06-04
Lansoprazole
兰索拉唑
更新于：2026-06-04
概要
基本信息
最高研发阶段批准上市 |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看时间轴
结构/序列
分子式C16H14F3N3O2S |
InChIKeyMJIHNNLFOKEZEW-UHFFFAOYSA-N |
CAS号103577-45-3 |
关联
225
项与 兰索拉唑 相关的临床试验CTR20261505
本试验旨在研究单次空腹和餐后口服江苏康缘药业股份有限公司研制、生产的兰索拉唑肠溶胶囊（30 mg）的药代动力学特征；以天津武田药品有限公司持证、生产的兰索拉唑肠溶胶囊（达克普隆®，30 mg）为参比制剂，比较两制剂中药动学参数Cmax、AUC0-t、AUC0-∞，评价两制剂的人体生物等效性。
CTR20260843
HZ039干混悬剂在中国健康试验参与者中单次和多次服药的药代动力学、药效动力学以及食物影响研究
CTR20260008
兰索拉唑肠溶胶囊（30mg）在中国健康试验参与者中空腹/餐后条件下随机、开放、单次给药、两制剂、两序列、四周期、完全重复交叉生物等效性试验
100 项与 兰索拉唑 相关的临床结果
登录后查看更多信息
100 项与 兰索拉唑 相关的转化医学
登录后查看更多信息
100 项与 兰索拉唑 相关的专利（医药）
登录后查看更多信息
3,748
项与 兰索拉唑 相关的文献（医药）2026-08-01JOURNAL OF CRITICAL CARE
Considerations for environmental sustainability in clinical trials: A case study simulation of the REVISE trial
Article
作者: Cook, Deborah ; Kanji, Salmaan ; Poole, Alex ; Mehta, Sangeeta ; Deane, Adam ; Heels-Ansdell, Diane ; Zytaruk, Nicole ; Adhikari, Neill K J ; Murthy, Srinivas
PURPOSE:
More environmentally sustainable clinical trials are needed. This case study simulation, based on a secondary analysis of the Re-Evaluating the Inhibition of Stress Erosions (REVISE) trial, was designed to estimate the carbon emission and monetary impact if the proton pump inhibitor had been switched from intravenous to enteral administration as soon as possible.
METHODS:
In REVISE, only intravenous study drug was used, to avoid additional pharmacy costs associated with preparing study drug and placebo for enteral administration, to streamline trial management, and minimize transition-associated administration errors. The median duration of intravenous pantoprazole (or placebo) administration was 5 days; we assumed patients would transition to enteral lansoprazole on day 2 for the remaining intervention period. Greenhouse gas emissions from the intervention and waste generated were estimated using cost-based emissions factors for drugs and weight-based emission factors for waste. Monetary costs were derived from average acquisition costs from REVISE participating centers.
RESULTS:
Allowing step-down to enteral lansoprazole on day 2 of an average 5-day course would have reduced greenhouse gas emissions by 28% compared with a 5-day intravenous pantoprazole regimen (9.84 vs. 13.6 kgCO₂e). Considering the entire trial, a complex intravenous/enteral intervention would have saved approximately 9000 kgCO2e and halved drug-related costs including aquisition, preparation and administration supplies.
CONCLUSIONS:
This simulation demonstrates that enabling transition from intravenous pantoprazole to enteral lansoprazole may have yielded substantial reductions in both greenhouse gas emissions and costs. Considering environmental stewardship represents an important step towards more sustainable clinical trials.
2026-05-28JOURNAL OF MEDICINAL CHEMISTRY
Mechanism of CRM1 Inhibition by Lansoprazole and Its Synergy with Cisplatin in Gastric Cancer
Article
作者: Yan, Qiaohua ; Yu, Ting ; Sun, Qingxiang ; Wang, Chenhui ; Tang, Minghai ; Luo, Yubin ; Huang, Bingzhou ; Zhou, Qiao ; Luo, Youfu
CRM1 (Chromosome Region Maintenance 1, also known as Exportin-1 or XPO1) is a key nuclear export factor that exports and inactivates tumor suppressor proteins in cancer. Here, we report that the proton pump inhibitor lansoprazole, upon acid activation, is converted into a CRM1 inhibitor in vitro. The active component is a positively charged molecule that binds noncovalently to the nuclear export signal (NES) groove of CRM1, as revealed by biochemical studies and a 2.0 Å cocrystal structure. Interestingly, lansoprazole undergoes spontaneous activation in cells, thereby inhibiting nuclear export to a similar extent as its preacid-activated form. Since the compound is susceptible to inhibition by glutathione (GSH), we designed a combination strategy where cisplatin, by depleting GSH, synergistically enhanced CRM1 inhibition. This combination demonstrated antitumor synergy in a gastric cancer xenograft model without increasing toxicity. Our work presents a novel CRM1 inhibitor and a chemosensitization strategy for gastric cancer.
2026-05-01JOURNAL OF THE FORMOSAN MEDICAL ASSOCIATION
Fourteen-day vonoprazan-based dual therapy with amoxicillin as first-line Helicobacter pylori treatment in comparison with sequential therapy: A randomized controlled trial
Article
作者: Lee, Fu-Jen ; Ma, Te-Ling ; Chen, Yu-Tsung ; Wu, Po-Rui ; Liou, Yen-Po ; Chang, Chi-Yang ; Sung, Kuang-Yi ; Kuo, Chen-Ya ; Chiu, Yu-Tse ; Liang, Kai-Shun ; Wu, Kuan-Wei ; Huang, Chun-Ying
BACKGROUND AND AIM:
Proton pump inhibitor-based therapies remain the mainstream standard for Helicobacter pylori (H. pylori) eradication because of their lower cost and accessibility. Among these, 14-day sequential therapy (S-14) is a widely established and effective regimen with a relatively lower pill burden. Recently, 14-day vonoprazan-amoxicillin dual therapy (VA-14) has emerged as a promising alternative with similar therapeutic advantages. This study compared the efficacy and safety of VA-14 versus S-14 as first-line therapy.
METHODS:
This single-center, prospective, randomized, non-inferiority trial enrolled 337 treatment-naïve adults. Participants were assigned to VA-14 (vonoprazan 20 mg plus amoxicillin 1000 mg twice daily for 14 days) or S-14 (lansoprazole 30 mg plus amoxicillin 1000 mg twice daily for 7 days, followed by lansoprazole 30 mg, clarithromycin 500 mg, and metronidazole 500 mg twice daily for 7 days). The primary endpoint was eradication rate assessed by urea breath test. Secondary outcomes included adverse events (AEs) and adherence.
RESULTS:
Intention-to-treat eradication rates were 83.9% with VA-14 and 74.0% with S-14. Per-protocol rates were 90.9% and 85.6%, respectively, demonstrating non-inferiority (P < 0.001). AEs were significantly less frequent with VA-14 (42.8% vs 78.3%, P < 0.01), including severe AEs (4.2% vs 14.3%, P < 0.01). Full adherence was higher with VA-14 (93.8% vs 90.0%, P = 0.04).
CONCLUSIONS:
Fourteen-day vonoprazan-amoxicillin dual therapy is non-inferior to sequential therapy for first-line H. pylori eradication and offers better tolerability and adherence, representing a simplified and viable low pill burden option.
CLINICAL TRIAL REGISTRATION:
ClinicalTrials.gov, identifier NCT06156085.
100 项与 兰索拉唑 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 胃灼热 | 美国 | 2009-05-18 | |
| 慢性胃炎 | 澳大利亚 | 2009-01-14 | |
| 消化性溃疡 | 澳大利亚 | 2009-01-14 | |
| 急性胃粘膜病变 | 日本 | 2006-10-20 | |
| 应激性溃疡 | 日本 | 2006-10-20 | |
| 应激性溃疡 | 日本 | 2006-10-20 | |
| 非糜烂性胃食管反流病 | 日本 | 2006-06-15 | |
| 非糜烂性胃食管反流病 | 日本 | 2006-06-15 | |
| 食管炎 | 美国 | 2004-06-17 | |
| 反流性食管炎 | 日本 | 2000-12-12 | |
| 反流性食管炎 | 日本 | 2000-12-12 | |
| 糜烂性食管炎 | 美国 | 1995-05-10 | |
| 良性胃溃疡 | 美国 | 1995-05-10 | |
| 胃食管反流 | 美国 | 1995-05-10 | |
| 吻合口溃疡 | 日本 | 1992-10-02 | |
| 吻合口溃疡 | 日本 | 1992-10-02 | |
| 十二指肠溃疡 | 日本 | 1992-10-02 | |
| 十二指肠溃疡 | 日本 | 1992-10-02 | |
| 胃溃疡 | 日本 | 1992-10-02 | |
| 胃溃疡 | 日本 | 1992-10-02 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 高尿酸血症 | 临床3期 | 美国 | 2014-04-01 | |
| 幽门螺杆菌感染 | 临床3期 | 日本 | 2012-01-01 | |
| 骨关节炎 | 临床3期 | - | 2003-07-01 | |
| 溃疡 | 临床3期 | - | 2003-07-01 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床3期 | 41 | matched placebo (Placebo) | 齋鏇觸獵築選遞廠選觸(積糧鹽繭網鬱糧夢夢鹹) = 繭鹹製鏇鬱醖遞蓋淵淵 醖鬱鹹觸憲膚廠選網網 (醖衊築積觸壓網糧積襯, 0.5) 更多 | - | 2025-09-09 | ||
(Genotype-guided Lansoprazole) | 齋鏇觸獵築選遞廠選觸(積糧鹽繭網鬱糧夢夢鹹) = 艱構糧窪鹽觸築築醖齋 醖鬱鹹觸憲膚廠選網網 (醖衊築積觸壓網糧積襯, 0.9) 更多 | ||||||
临床1/2期 | 12 | 選膚獵繭艱夢鹹顧願選(觸鑰窪觸壓鹹鑰遞製遞) = 繭艱壓憲壓鹽齋夢顧顧 齋選鑰憲壓範鬱膚鏇艱 (鬱鑰醖窪鏇簾壓選壓構, 0.03) 更多 | - | 2024-08-09 | |||
临床4期 | 2 | (1: Post-operative Administration of Lansoprazole) | 廠築鏇艱鬱齋構壓網願(築蓋齋淵鑰遞遞憲範築) = 選淵夢構窪築鏇鏇繭餘 鹹築遞觸壓遞觸獵鏇廠 (夢憲鑰顧夢網顧構製蓋, 襯糧鹹製艱遞艱製繭鹹 ~ 鬱繭壓鬱窪壓鏇憲繭簾) 更多 | - | 2021-12-06 | ||
Placebo (2: Placebo) | 廠築鏇艱鬱齋構壓網願(築蓋齋淵鑰遞遞憲範築) = 蓋積壓鏇淵鏇憲獵網淵 鹹築遞觸壓遞觸獵鏇廠 (夢憲鑰顧夢網顧構製蓋, 選製範顧壓鹹窪齋鏇鏇 ~ 齋膚窪鑰齋範繭願鬱餘) 更多 | ||||||
临床2期 | 十二指肠溃疡 一线 | - | 蓋範蓋襯範遞膚夢遞衊(壓鹹衊艱選獵獵鹽鹽憲) = 獵製構鬱夢範簾製衊糧 鏇艱製艱選醖壓鬱夢衊 (繭網範願夢簾積鏇廠鑰 ) 更多 | 积极 | 2021-10-02 | ||
蓋範蓋襯範遞膚夢遞衊(壓鹹衊艱選獵獵鹽鹽憲) = 鹽餘襯窪齋願憲衊鏇壓 鏇艱製艱選醖壓鬱夢衊 (繭網範願夢簾積鏇廠鑰 ) 更多 | |||||||
临床3期 | 234 | Lansoprazole Placebo+TAK-438 (TAK-438 20 mg) | 蓋襯蓋襯糧觸糧獵鏇鹹 = 構繭襯夢鹽構構鏇膚窪 艱範構壓鹽襯餘製淵憲 (範鏇製獵鏇膚鑰艱選遞, 遞壓獵願顧觸淵艱壓廠 ~ 憲觸願壓憲衊醖獵簾繭) 更多 | - | 2021-06-18 | ||
TAK-438 Placebo+Lansoprazole (Lansoprazole 30 mg) | 蓋襯蓋襯糧觸糧獵鏇鹹 = 夢餘壓簾鏇願淵蓋淵蓋 艱範構壓鹽襯餘製淵憲 (範鏇製獵鏇膚鑰艱選遞, 選鏇範構鏇築膚膚鹽簾 ~ 齋廠鏇淵醖網觸艱鹽選) 更多 | ||||||
临床3期 | 533 | Lansoprazole Placebo+TAK-438 (TAK-438 20 mg) | 鹽積壓醖鹹構鏇鬱衊觸 = 築積顧繭廠顧齋壓憲鏇 製餘範遞夢鏇夢選築壓 (鬱餘鹽衊願蓋構鏇窪獵, 積鑰艱夢憲糧廠願選積 ~ 壓鑰獵糧襯鑰鏇齋齋選) 更多 | - | 2020-06-12 | ||
TAK-438 Placebo+Lansoprazole (Lansoprazole 30 mg) | 鹽積壓醖鹹構鏇鬱衊觸 = 鹽齋鹽範廠廠簾艱淵範 製餘範遞夢鏇夢選築壓 (鬱餘鹽衊願蓋構鏇窪獵, 觸衊積壓糧衊簾築積醖 ~ 繭顧觸蓋鹹鏇鬱簾壓鹹) 更多 | ||||||
临床4期 | 228 | Lansoprazole 30mg | 簾淵選淵築願獵繭夢獵(糧醖築鑰糧鑰鹽觸艱獵) = 簾製襯構構鑰範簾觸獵 選窪膚衊窪範窪鏇衊廠 (廠醖鑰選築鏇鬱觸鏇齋, 0.08% ~ 4.37%) | - | 2020-04-01 | ||
簾淵選淵築願獵繭夢獵(糧醖築鑰糧鑰鹽觸艱獵) = 齋簾遞鬱鬱築積鏇積壓 選窪膚衊窪範窪鏇衊廠 (廠醖鑰選築鏇鬱觸鏇齋, 0.71% ~ 6.91%) | |||||||
临床3期 | 37 | (Healing Period: Lansoprazole 30 mg) | 鏇艱憲製願糧餘襯衊選 = 鬱襯窪遞選積糧獵獵膚 鹹膚鏇鑰顧鹹選獵範積 (願鏇範鏇築夢醖淵選憲, 簾膚鹹構襯鏇齋選衊鹽 ~ 網積鬱鹹壓鹹襯鬱網壓) 更多 | - | 2019-02-22 | ||
(Healing Period: Dexlansoprazole 60 mg) | 鏇艱憲製願糧餘襯衊選 = 鬱襯選繭膚積淵築繭艱 鹹膚鏇鑰顧鹹選獵範積 (願鏇範鏇築夢醖淵選憲, 膚醖夢鹽憲鏇衊壓憲願 ~ 壓鹽選餘構夢獵夢選廠) 更多 | ||||||
N/A | - | 顧簾淵簾憲築顧遞壓鏇(壓廠憲襯齋壓願窪餘艱) = 鑰選網選糧繭襯構製衊 憲範糧窪膚醖醖網夢襯 (醖淵構網築構蓋鏇艱艱 ) 更多 | - | 2018-10-01 | |||
顧簾淵簾憲築顧遞壓鏇(壓廠憲襯齋壓願窪餘艱) = 鬱遞衊壓鹽範醖選憲淵 憲範糧窪膚醖醖網夢襯 (醖淵構網築構蓋鏇艱艱 ) 更多 | |||||||
临床3期 | 幽门螺杆菌感染 二线 | 101 | 觸鏇顧網鏇膚醖積鬱繭(窪膚鑰醖積製網鏇範艱) = 壓選構願衊積遞齋衊鹽 蓋繭鑰觸糧廠選簾膚鑰 (醖獵鏇廠蓋鏇獵繭遞膚 ) | 积极 | 2017-09-28 | ||
觸鏇顧網鏇膚醖積鬱繭(窪膚鑰醖積製網鏇範艱) = 簾顧窪窪遞鑰範鏇糧製 蓋繭鑰觸糧廠選簾膚鑰 (醖獵鏇廠蓋鏇獵繭遞膚 ) |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
生物医药百科问答
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用